NCT05164055View on ClinicalTrials.gov

Avalglucosidase Alfa French Post-trial Access for Participants With Pompe Disease (PTA Avalglucosidase)

PHASE4Active, not recruitingINTERVENTIONAL
Enrollment

17

Participants

Timeline

Start Date

July 11, 2022

Primary Completion Date

December 31, 2025

Study Completion Date

December 31, 2025

Conditions
Glycogen Storage Disease Type II
Interventions
DRUG

Avalglucosidase alfa (GZ402666)

Pharmaceutical form: Sterile lyophilized powder Route of administration: intravenous (IV) infusion

Trial Locations (11)

13385

Investigational Site Number : 2500001, Marseille

29609

Investigational Site Number : 2500005, Brest

33000

Investigational Site Number : 2500004, Bordeaux

37044

Investigational Site Number : 2500011, Tours

44093

Investigational Site Number : 2500006, Nantes

59037

Investigational Site Number : 2500009, Lille

63000

Investigational Site Number : 2500008, Clermont-Ferrand

69003

Investigational Site Number : 2500003, Lyon

75013

Investigational Site Number : 2500002, Paris

75015

Investigational Site Number : 2500010, Paris

06200

Investigational Site Number : 2500007, Nice

All Listed Sponsors
lead

Genzyme, a Sanofi Company

INDUSTRY

NCT05164055 - Avalglucosidase Alfa French Post-trial Access for Participants With Pompe Disease (PTA Avalglucosidase) | Biotech Hunter | Biotech Hunter